{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06460844",
            "orgStudyIdInfo": {
                "id": "RTx-015-CP-101"
            },
            "organization": {
                "fullName": "Ray Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa Patients",
            "officialTitle": "Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-015 in Patients With Retinitis Pigmentosa",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-evaluate-safety-of-rtx-injection-in-retinitis-pigmentosa-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-10",
            "studyFirstSubmitQcDate": "2024-06-13",
            "studyFirstPostDateStruct": {
                "date": "2024-06-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Ray Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 9 eligible patients with retinitis pigmentosa will be enrolled sequentially in up to 3 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 12 months.",
            "detailedDescription": "This Phase 1, open-label, non-randomized, multicenter clinical trial is to evaluate the safety and preliminary efficacy of a single, uniocular intravitreal injection of an investigational optogenetic gene therapy, RTx-015, in patients with retinitis pigmentosa. Up to 3 dose cohorts are planned, and each cohort will consist initially of 3 patients. Eligible patients will be assigned to a dose cohort by sequential enrollment."
        },
        "conditionsModule": {
            "conditions": [
                "Retinitis Pigmentosa"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 9,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Low Dose RTx-015",
                    "type": "EXPERIMENTAL",
                    "description": "Single intravitreal injection of low dose RTx-015",
                    "interventionNames": [
                        "Genetic: RTx-015"
                    ]
                },
                {
                    "label": "Middle Dose RTx-015",
                    "type": "EXPERIMENTAL",
                    "description": "Single intravitreal injection of middle dose RTx-015",
                    "interventionNames": [
                        "Genetic: RTx-015"
                    ]
                },
                {
                    "label": "High Dose RTx-015",
                    "type": "EXPERIMENTAL",
                    "description": "Single intravitreal injection of high dose RTx-015",
                    "interventionNames": [
                        "Genetic: RTx-015"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "RTx-015",
                    "description": "Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.",
                    "armGroupLabels": [
                        "High Dose RTx-015",
                        "Low Dose RTx-015",
                        "Middle Dose RTx-015"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events",
                    "description": "The number of patients in each cohort with treatment-emergent adverse events categorized using MedDRA v24.0 or higher",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Best Corrected Visual Acuity (BCVA) at Month 6 and Month 12",
                    "description": "Change from baseline to Month 6 and Month 12 after injection with RTx-015 in BCVA",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Low Luminance Visual Acuity (LLVA) at Month 6 and Month 12",
                    "description": "Change from baseline to Month 6 and Month 12 after injection with RTx-015 in LLVA",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Multi luminance mobility at Month 6 and Month 12",
                    "description": "Change from baseline to Month 6 and Month 12 after injection with RTx-015 in Visual Change from baseline to Month 6 and 12 in mobility performance at multiple luminance levels",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Contrast Sensitivity at Month 6 and Month 12",
                    "description": "Change from baseline to Month 6 and Month 12 after injection with RTx-015 in Contrast Sensitivity",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Full-field static visual field testing at Month 6 and Month 12",
                    "description": "Change from baseline to Month 6 and Month 12 after injection with RTx-015 in the total area in which objects can be seen",
                    "timeFrame": "6 and 12 Months"
                },
                {
                    "measure": "Low Vision Quality of Life at Month 6 and Month 12",
                    "description": "Change from baseline in low vision quality of life at Month 6 and Month 12. An algorithm will be applied to assess a total score. Higher scores are a worsening of the condition.",
                    "timeFrame": "6 and 12 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults \u226518 years of age\n* Informed consent obtained from the patient\n* Clinical diagnosis of Retinitis Pigmentosa independent of causative mutation\n* Study eye and fellow eye Best Corrected Visual Acuity meeting study criteria\n* Presence of retinal ganglion cells and/or retinal nerve fiber layer on Spectral Domain Optical Coherence Tomography testing at Screening confirmed by central image reading center\n* Adequate organ function and general good health\n\nExclusion Criteria:\n\n* Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent, or therapy in the past six months\n* Concurrent participation in another interventional clinical ocular study\n* Prior receipt of any gene therapy (ocular or other), retinal implant, or ocular cell therapy\n* Pre-existing eye conditions in either eye that would preclude the planned treatment or, in the opinion of the Investigator, are significant enough to interfere with the interpretation of study endpoints or procedural complications\n* Known steroid responders if their intraocular pressure was not able to be managed effectively with topical pressure-lowering medications after prior use of steroid medications\n* Complicating systemic diseases; complicating systemic diseases include those in which the disease itself, or the treatment for the disease, can alter ocular and/or Central Nervous System (CNS) function (e.g., radiation treatment of the orbit; leukemia with CNS/optic nerve involvement)\n* Any immunological response dysfunction including, immuno-compromising diseases or use of immunosuppressive medications, among others\n* Cataract or other ocular (including refractive) surgery, intraocular and/or peri-ocular injection in either eye within the prior four months (i.e., 120 days) prior to screening\n* Prior vitrectomy or aphakia in the study eye\n* Known sensitivity to any component of the study treatment or contraindication to medications planned for use in the peri-procedural period (e.g., povidone-iodine to prep for intravitreal injection)\n* Known contraindication to prophylactic steroid regimen\n* Current pregnancy or breastfeeding\n* Any other condition that would not allow the patient to complete follow-up examinations during the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Executive Medical Director",
                    "role": "CONTACT",
                    "phone": "+1 858 617 8610",
                    "email": "clinicaltrials@raytherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Retina Vitreous Associates Medical Group",
                    "city": "Beverly Hills",
                    "state": "California",
                    "zip": "90211",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "David Boyer, MD",
                            "role": "CONTACT",
                            "phone": "310-289-2478",
                            "phoneExt": "3"
                        },
                        {
                            "name": "David Boyer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.07362,
                        "lon": -118.40036
                    }
                },
                {
                    "facility": "UCI Alpha Clinic",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "UCI Alpha Clinic",
                            "role": "CONTACT",
                            "phone": "949-824-3990",
                            "email": "alphaclinic@hs.uci.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012173",
                    "term": "Retinitis"
                },
                {
                    "id": "D000012174",
                    "term": "Retinitis Pigmentosa"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012164",
                    "term": "Retinal Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                },
                {
                    "id": "D000015785",
                    "term": "Eye Diseases, Hereditary"
                },
                {
                    "id": "D000058499",
                    "term": "Retinal Dystrophies"
                },
                {
                    "id": "D000012162",
                    "term": "Retinal Degeneration"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15008",
                    "name": "Retinitis",
                    "asFound": "Retinitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15009",
                    "name": "Retinitis Pigmentosa",
                    "asFound": "Retinitis Pigmentosa",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14999",
                    "name": "Retinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M18339",
                    "name": "Eye Diseases, Hereditary",
                    "relevance": "LOW"
                },
                {
                    "id": "M29107",
                    "name": "Retinal Dystrophies",
                    "relevance": "LOW"
                },
                {
                    "id": "M14997",
                    "name": "Retinal Degeneration",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T4945",
                    "name": "Retinitis Pigmentosa",
                    "asFound": "Retinitis Pigmentosa",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}